The patent dispute between Roche (the Swiss drugmaker) and Shire (London-based drugmaker) has escalated this week, after Shire filed a new motion in a U.S. court. The motion aims, according to Roche, to stop some patients getting the medicine they require. The patent dispute is over Roche’s new haemophilia drug – Hemlibra.  There are about 20,000 people in the United States with the disease and 400,000 worldwide, according to the National Hemophilia Foundation.

Shire’s motion for a preliminary injunction is part of an ongoing case in which it contends Roche infringed on a key patent to develop Hemlibra, approved in November by the U.S. Food and Drug Administration.

The patent dispute at the U.S. district court of Delaware underscores Hemlibra’s potential to take business from Shire, with some analysts estimating Roche’s roughly $450,000-per-year drug will hit $5 billion in annual sales by muscling in on older drugs for the genetic disease whose sufferers’ blood does not clot properly. In a press release late last week, Shire said it expected a judge to rule next year.

“Until the court’s decision on the motion for the preliminary injunction, expected summer 2018, is made there will be no patient impact,” Shire said in a statement. “Shire has proactively proposed a carve-out provision to facilitate access for patients, but the scope of the provision is ultimately a matter for the court to decide.”

In the patent dispute, Roche argues Shire’s patent is not valid and that its scientists did not encroach on its rival’s intellectual property.

On Saturday, however, the Swiss company acknowledged that Shire’s latest motion would have no immediate impact on the current situation in which Hemlibra is approved for so-called “inhibitor patients,” or those who have developed resistance to clotting treatments like those made by Shire. Nonetheless, they contend Shire’s motion to encroach on decisions best left to doctors and patients. “We believe it is also inappropriate for Shire to dictate which patients should or should not receive Hemlibra,” the company said in a statement.

Subscribe To Our Newsletter

Would you like to receive our popular weekly news alerts straight to your inbox? Solely patent focused and only sent once a week means you can guarantee there will be something you are interested in reading instead of clogging up your inbox with junk. Sign up now!

You have Successfully Subscribed!